ACRV — Acrivon Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1781174 ·
Last close
$1.48
Market Cap
$63.35M
52W High
$2.24
52W Low
$1.27
ADV30
461,297
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -19,902,000 | -19,042,000 | 107,832,000 | 34,064,000 | 12,317,000 |
| Dec 2025 | 0 | — | -20,116,000 | -18,985,000 | 129,717,000 | 41,499,000 | 17,201,000 |
| Sep 2025 | 0 | — | -19,687,000 | -18,234,000 | 145,299,000 | 35,405,000 | 16,696,000 |
| Jun 2025 | 0 | — | -22,649,000 | -21,006,000 | 158,583,000 | 41,895,000 | 15,546,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-64,668,000
Investing CF
$60,013,000
Financing CF
$-439,000
CapEx
$-1,625,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.02
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-293,923,000
Inventory
—
Receivables
—
ST Investments
$63,673,000
EBIT TTM
$-82,354,000
Pretax Income TTM
$-77,267,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -84,114,000 | -77,905,000 | 129,717,000 | 17,201,000 | — | -63,665,000 |
| Dec 2024 | 0 | -89,199,000 | -80,556,000 | 196,588,000 | 19,802,000 | — | -65,669,000 |
| Dec 2023 | 0 | -67,103,000 | -60,388,000 | 138,265,000 | 17,070,000 | — | -42,641,000 |
| Dec 2022 | 0 | -32,657,000 | -31,167,000 | 181,226,000 | 10,751,000 | — | -30,117,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.95
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IBO | IMPACT BIOMEDICAL INC. | $63.08M | $0.58 | — |
| BYSI | BeyondSpring Inc. | $64.56M | $1.57 | — |
| CTOR | CITIUS ONCOLOGY, INC. | $61.74M | $0.66 | — |
| CING | Cingulate Inc. | $65.73M | $4.88 | — |
| MNOV | MEDICINOVA INC | $60.54M | $1.23 | — |
News headlines (Yahoo Finance, 1h cache)
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
2026-05-21 11:30 · Yahoo
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 20:00 · Yahoo
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
2026-05-13 20:10 · Yahoo
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Develo
2026-04-17 20:00 · Yahoo
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2026-03-19 11:21 · Yahoo
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immun
2026-03-17 21:54 · Yahoo
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why
2026-03-03 17:00 · Yahoo
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer
2026-02-27 16:47 · Yahoo
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
2026-02-24 13:00 · Yahoo
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
2026-02-23 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.